ArticleBMC biotechnology2025
Green synthesis of silver nanoparticles using Keratinase from Pseudomonas aeruginosa-C1M, characterization and applications as novel multifunctional biocatalyst.
Article in BMC biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Green-synthesized silver nanoparticles from fresh and wasteRSC advances · 2026Article
- Article
- Green Synthesis of Silver Nanoparticles fromMolecules (Basel, Switzerland) · 2026Article
- Laccase-mediated silver nanoparticles as a nano-biocatalytic pretreatment platform for enhanced saccharification and bioethanol production from sugarcane bagasse.World journal of microbiology & biotechnology · 2026Article
- Keratinases: microbial sources, mechanisms, and industrial applications in waste valorization.Frontiers in microbiology · 2026Review
- Article
- Microbial-Based Green Synthesis of Silver Nanoparticles: A Comparative Review of Bacteria- and Fungi-Mediated Approaches.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionThis study explores the biogenic synthesis of silver nanoparticles (AgNPs) using keratinase from Pseudomonas aeruginosa-C1M as a reducing and stabilizing agent. The synthesis of AgNPs was characterized by a color change from transparent to dark brown and a UV-Vis absorption peak at 450 nm, confirming nanoparticle formation. The study further investigates the structural, morphological, and functional properties of these AgNPs, particularly their antibacterial activity and their potential role in azo dye decontamination. METHODS AND
resultsThe FTIR confirmed that AgNPs nanoparticles formation with keratinase. X-ray diffraction analysis showed that the prepared AgNPs were crystalline in nature and had face-centered cubic lattice planes. When observed under the transmission electron microscope and scanning electron microscope the nanoparticles were monodispersed spheres of different sizes. The diameter of the AgNPs was ~ 119 nm according to dynamic light scattering. High dispersion, long-term stability and excellent colloidal properties were supported by a high negative zeta potential value. The silver nanoparticles were found to have an antibacterial activity with zone of inhibition 25 mm and 33 mm against pathogenic strains of Staphylococcus aureus and Escherichia coli respectively. The synthesized zero-valent silver nanoparticles assisted in the decontamination of azo dyes (methyl red, methyl orange, safranin O and methyl violet) through the incorporation of sodium borohydride and light-catalyzed processes.
conclusionThis study demonstrates, for the first time, that keratinase from Pseudomonas aeruginosa-C1M can be used for AgNPs synthesis. The biogenic AgNPs exhibited potent antibacterial activity and played a crucial role in detoxifying hazardous azo dyes. These findings highlight the dual-functional potential of AgNPs for applications in antimicrobial treatments and environmental remediation. Future studies should explore their mechanism of action, scalability, and industrial applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.